Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fish and Richardson
Federal Trade Commission
Boehringer Ingelheim
Queensland Health
Harvard Business School

Generated: December 18, 2017

DrugPatentWatch Database Preview

Details for Patent: 5,763,483

« Back to Dashboard

Which drugs does patent 5,763,483 protect, and when does it expire?

Patent 5,763,483 protects TAMIFLU and is included in two NDAs. There have been three Paragraph IV challenges on Tamiflu.

Protection for TAMIFLU has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

Summary for Patent: 5,763,483

Title: Carbocyclic compounds
Abstract:Novel carbocyclic compounds are described. The compounds generally comprise an acidic group, a basic group, a substituted amino or N-acyl and a group having an optionally hydroxylated alkane moiety. Pharmaceutical compositions comprising the inhibitors of the invention are also described. Methods of inhibiting neuraminidase in samples suspected of containing neuraminidase are also described. Antigenic materials, polymers, antibodies, conjugates of the compounds of the invention with labels, and assay methods for detecting neuraminidase activity are also described.
Inventor(s): Bischofberger; Norbert W. (San Carlos, CA), Kim; Choung U. (San Carlos, CA), Lew; Willard (San Mateo, CA), Liu; Hongtao (Foster City, CA), Williams; Matthew A. (Foster City, CA)
Assignee: Gilead Sciences, Inc. (Foster City, CA)
Application Number:08/774,345
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
RocheTAMIFLUoseltamivir phosphateCAPSULE;ORAL021087-003Jul 2, 2007ABRXYesNo► Subscribe► SubscribeY► Subscribe
RocheTAMIFLUoseltamivir phosphateCAPSULE;ORAL021087-002Jul 2, 2007ABRXYesNo► Subscribe► SubscribeY► Subscribe
RocheTAMIFLUoseltamivir phosphateCAPSULE;ORAL021087-001Oct 27, 1999ABRXYesYes► Subscribe► SubscribeY► Subscribe
RocheTAMIFLUoseltamivir phosphateFOR SUSPENSION;ORAL021246-002Mar 21, 2011ABRXYesYes► Subscribe► SubscribeY► Subscribe
RocheTAMIFLUoseltamivir phosphateFOR SUSPENSION;ORAL021246-001Dec 14, 2000DISCNNoNo► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Fish and Richardson
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch: